<SEC-DOCUMENT>0001213900-21-007904.txt : 20210210
<SEC-HEADER>0001213900-21-007904.hdr.sgml : 20210210
<ACCEPTANCE-DATETIME>20210210060843
ACCESSION NUMBER:		0001213900-21-007904
CONFORMED SUBMISSION TYPE:	FWP
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20210210
DATE AS OF CHANGE:		20210210

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-232009
		FILM NUMBER:		21609142

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Enlivex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001596812
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		FWP

	BUSINESS ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042
		BUSINESS PHONE:		972 (0) 3 7326616

	MAIL ADDRESS:	
		STREET 1:		37 DEREH MENACHEM BEGIN ST.
		STREET 2:		15TH FLOOR
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6522042

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bioblast Pharma Ltd.
		DATE OF NAME CHANGE:	20160919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIO BLAST PHARMA LTD.
		DATE OF NAME CHANGE:	20140113
</SEC-HEADER>
<DOCUMENT>
<TYPE>FWP
<SEQUENCE>1
<FILENAME>ea135100-fwp_enlivex.htm
<DESCRIPTION>FWP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="color: rgb(0, 0, 0); font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0px; background-color: white"><B>Free
Writing Prospectus dated February 9, 2021</B></P>

<P STYLE="color: rgb(0, 0, 0); font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0px; background-color: white"><B>Filed
pursuant to Rule 433</B></P>

<P STYLE="color: rgb(0, 0, 0); font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0px; background-color: white"><B>Relating
to the Preliminary Prospectus Supplement dated</B></P>

<P STYLE="color: rgb(0, 0, 0); font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0px; background-color: white"><B>February
9, 2021</B></P>

<P STYLE="color: rgb(0, 0, 0); font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0px; background-color: white"><B>Registration
Statement Nos.&nbsp;333-232009 and 333-252926</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>Enlivex Increases
Previously Announced Bought</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>Deal Offering to
Approximately $46.0 Million of Ordinary Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>Nes Ziona,
Israel, Feb. 9, 2021,&nbsp;</B>Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a clinical-stage macrophage reprogramming
immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, today announced that
due to demand, the underwriter has agreed to increase the size of the previously announced offering and purchase on a firm
commitment basis 2,296,107 ordinary shares, par value NIS 0.40 per share, of the Company at a price to the public of $20.00
per ordinary share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about
February 12, 2021, subject to satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">H.C. Wainwright &amp;
Co. is acting as the sole book-running manager for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company also has
granted to the underwriter a 30-day option to purchase up to 344,416 additional ordinary shares at the public offering price, less
underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The gross proceeds
to Enlivex, before deducting underwriting discounts and commissions and offering expenses and assuming no exercise of the underwriter&rsquo;s
option to purchase additional ordinary shares, are expected to be approximately $46.0 million. The Company intends to use the
net proceeds from this offering for (i) clinical, regulatory, manufacturing and research and development activities; (ii) potential
acquisitions and in-licensing; and (iii) other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The securities
described above are being offered by Enlivex pursuant to a &ldquo;shelf&rdquo; registration statement on Form F-3 (File No.
333-232009) previously filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on June 7, 2019 and declared
effective by the SEC on June 21, 2019 and the Form F-3MEF filed on February 9, 2021 (File No. 333-252926). The offering
of the securities is being made only by means of a prospectus, including a prospectus supplement, forming a part of the
effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the securities
being offered have been filed with the SEC and are available on the SEC's website at&nbsp;<U>http://www.sec.gov</U>.&nbsp; A
final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and, upon filing,
may be obtained on the SEC's website at&nbsp;<U>http://www.sec.gov</U>&nbsp;or by contacting H.C. Wainwright &amp; Co., LLC
at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (646) 975-6996 or e-mail
at&nbsp;<U>placements@hcwco.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">This press release
shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state or other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><B>About Enlivex</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0; margin-left: 0; background-color: white">Enlivex
is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra<SUP>TM</SUP>, a universal, off-the-shelf
cell therapy designed to&nbsp;reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their
homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information,
visit&nbsp;http://www.enlivex.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>Safe Harbor Statement:&nbsp;
This press release contains forward-looking statements, which may be identified by words such as &ldquo;expects,&rdquo; &ldquo;plans,&rdquo;
&ldquo;projects,&rdquo; &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;should,&rdquo;
&ldquo;would&rdquo;, &ldquo;could,&rdquo; &ldquo;intends,&rdquo; &ldquo;estimates,&rdquo; &ldquo;suggests,&rdquo; &ldquo;has the
potential to&rdquo; and other words of similar meaning, including statements regarding expected cash balances, market opportunities
for the results of current clinical studies and preclinical experiments, the effectiveness of, market opportunities for, ALLOCETRA<SUP>TM</SUP>&nbsp;programs,
and statements relating to the bought deal offering, including as to the consummation of the offering described above, the expected
proceeds from the offering, the intended use of proceeds and the timing of the closing of the offering. All such forward-looking
statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.&nbsp; Investors
are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex&rsquo;s business and prospects,
including market and other conditions and the risks that Enlivex may not succeed in generating any revenues or developing any commercial
products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate
data that would support the approval or marketing of these products for the indications being studied or for other indications;
that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results
to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce
results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may
differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA<SUP>TM</SUP>&nbsp;product
line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional
time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive
products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.&nbsp;
In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological
and other factors discussed in Enlivex&rsquo;s filings with the Securities and Exchange Commission, including in the Company&rsquo;s
most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.&nbsp; The forward-looking statements
contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update
forward-looking statements, except as required under applicable law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">ENLIVEX CONTACT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Shachar Shlosberger,
CFO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Enlivex Therapeutics,
Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">shachar@enlivexpharm.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">INVESTOR RELATIONS
CONTACT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Eric Ribner</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">LifeSci Advisors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">eric@lifesciadvisors.com</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
